Immunotherapy-related cognitive impairment after CAR T cell therapy in mice.

CAR T cell therapy is a powerful and increasingly common cancer treatment that reprograms a patient's own immune cells to hunt down and destroy tumor cells. It has transformed outcomes for many cancer patients. But like many effective cancer treatments, it may come with a downside: emerging evidence suggests it can affect thinking and memory, similar to the "chemo brain" some patients describe after chemotherapy. Until now, scientists haven't had a clear picture of why this happens or whether anything can be done about it. This study used mouse models to investigate the issue directly. The researchers gave mice CAR T cell therapy for both brain tumors and tumors located elsewhere in the body, and found that both types caused measurable declines in cognitive function. This happened alongside a long-lasting immune reaction inside the brain itself. Specifically, the treatment activated microglia — the brain's resident immune cells — particularly in the brain's white matter (the tissue that helps different brain regions communicate with each other). These activated microglia released inflammatory signaling molecules called chemokines, and similar inflammatory molecules also showed up at elevated levels in the fluid surrounding the brain and spinal cord. This ongoing inflammation had real consequences for brain health. It disrupted the normal function of oligodendrocytes, the cells responsible for maintaining the protective insulation around nerve fibers, and it interfered with the ongoing production of new neurons in the hippocampus, a brain region crucial for learning and memory. To confirm these findings were relevant to humans, the researchers examined brain tissue from patients who had previously received CAR T cell therapy for tumors near the brainstem, using a technique that reads gene activity in individual cell nuclei. This human tissue showed the same pattern seen in mice: reactive, agitated states in both microglia and oligodendrocytes following treatment. Most encouragingly, the researchers identified a way to potentially reverse this damage. When they temporarily reduced the number of microglia in treated mice, or blocked a specific chemical signaling receptor called CCR3, the oligodendrocyte problems resolved and the mice's cognitive performance improved, as measured by tests of attention and short-term memory. Taken together, these findings help explain why CAR T cell therapy may sometimes lead to cognitive side effects, revealing a chain of events involving brain immune cells, inflammation, and disrupted brain cell maintenance. Importantly, the study also points to specific, targetable steps in this process — such as blocking the CCR3 receptor — that could potentially prevent or treat these cognitive side effects in patients, without undermining the cancer-fighting power of the therapy itself. While this research was conducted in mice and would need further studies before any treatment could be tested in humans, it represents an important step toward making powerful immunotherapies safer for the brain as well as effective against cancer.